Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
0.5681
-0.0189 (-3.22%)
At close: Jun 6, 2025, 4:00 PM
0.5731
+0.0050 (0.88%)
Pre-market: Jun 9, 2025, 5:09 AM EDT
Windtree Therapeutics Employees
Windtree Therapeutics had 14 employees as of December 31, 2024. The number of employees decreased by 6 or -30.00% compared to the previous year.
Employees
14
Change
-6
Growth
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$1,482,071
Market Cap
2.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
WINT News
- 17 days ago - Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 - GlobeNewsWire
- 27 days ago - Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025 - GlobeNewsWire
- 4 weeks ago - Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US - GlobeNewsWire
- 2 months ago - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - PRNewsWire
- 2 months ago - Evofem Reports Fourth Consecutive Year of Net Sales Growth - PRNewsWire
- 2 months ago - Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules - GlobeNewsWire
- 2 months ago - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product - GlobeNewsWire
- 5 months ago - Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline - GlobeNewsWire